See more : Sika AG (SXYAY) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maruha Nichiro Corporation (1333.T) Income Statement Analysis – Financial Results
- Katare Spinning Mills Limited (KATRSPG.BO) Income Statement Analysis – Financial Results
- Qualicorp Consultoria e Corretora de Seguros S.A. (QUAL3.SA) Income Statement Analysis – Financial Results
- PipeHawk plc (PIP.L) Income Statement Analysis – Financial Results
- Epiroc AB (publ) (EPI-B.ST) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
| Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
| Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
| Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
Rosen, National Trial Counsel, Reminds Odonate Therapeutics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ODT
New York, New York--(Newsfile Corp. - October 30, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT
New York, New York--(Newsfile Corp. - October 28, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. ("Odonate") (NASDAQ: ODT) between December...
ROSEN, NATIONAL TRIAL LAWYERS, Reminds Odonate Therapeutics, Inc. Investors of Important November 16 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ODT
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of...
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30,...
SHAREHOLDER ALERT: ODT NXTC FLDM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
October 05, 2020 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / October 5, 2020 / The Law Offices of Vincent Wong announce that class actions have...
Wall Street Breakfast: What Moved Markets
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Odonate Therapeutics to Hold Conference Call on Monday, August 24, 2020 at 8:30 a.m. ET
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24,...
Odonate Therapeutics (NASDAQ:ODT) Rating Lowered to Sell at BidaskClub
BidaskClub lowered shares of Odonate Therapeutics (NASDAQ:ODT) from a hold rating to a sell rating in a research report sent to investors on Thursday morning, BidAskClub reports. A number of other analysts have also recently commented on the company. Zacks...
BidaskClub Lowers Odonate Therapeutics (NASDAQ:ODT) to Hold
Odonate Therapeutics (NASDAQ:ODT) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Monday, BidAskClub reports. Separately, Zacks Investment Research downgraded shares of Odonate Therapeutics from a “buy” rating...
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) Adverum Biotechnologies Inc...
Source: https://incomestatements.info
Category: Stock Reports